CAMP4 Therapeutics Advances SYNGAP1 Gene Therapy Toward Clinical Testing with GLP Toxicology Studies
核心洞察
CAMP4 Therapeutics (搜索) has initiated Good Laboratory Practice toxicology studies for CMP-SYNGAP-01 (搜索), an antisense oligonucleotide therapy designed to restore SYNGAP1 protein levels in neurodevelopmental disorders (搜索).
The company plans to submit a clinical trial application that could enable a first-in-human Phase 1/2 trial as early as the second half of 2026 for SYNGAP1-related disorders (搜索).
SYNGAP1-related disorders (搜索) represent 0.5% to 1.0% of all intellectual disability (搜索) cases and currently have no FDA-approved disease-modifying therapies available.
CAMP4 Therapeutics (搜索) Corporation has initiated Good Laboratory Practice (GLP) toxicology studies for its lead product candidate CMP-SYNGAP-01 (搜索), marking a critical milestone toward clinical testing of a potential first-in-class therapy for SYNGAP1-related neurodevelopmental disorders (搜索). The Cambridge-based clinical-stage biopharmaceutical company announced that these regulatory-compliant studies will support a planned clinical trial application, potentially enabling initiation of a first-in-human Phase 1/2 clinical trial as early as the second half of 2026.
Addressing a Significant Unmet Medical Need
SYNGAP1-related disorders (搜索) represent a group of neurodevelopmental conditions caused by pathogenic variants in the SYNGAP1 gene that result in haploinsufficiency, reducing SYNGAP (搜索) protein levels by up to 50%. The SYNGAP protein plays a critical role in cognitive development and synaptic function, and disorders related to its deficiency are reported to represent 0.5% to 1.0% of all intellectual disability (搜索) cases, making them among the most common causes of intellectual disability in patients with epilepsy (搜索).
Currently, no FDA-approved, disease-modifying therapies exist for SYNGAP1-related disorders (搜索). Treatment is often limited to supportive physical, occupational, and speech therapy, with physicians sometimes prescribing a combination of non-specific anti-seizure drugs and other medications. However, SYNGAP1-related disorders have proven difficult to control with available therapeutics, highlighting the urgent need for targeted interventions.
Novel Antisense Oligonucleotide Approach
CMP-SYNGAP-01 (搜索) represents an investigational, novel approach that targets the SYNGAP1 gene at the transcriptional level to restore SYNGAP (搜索) function and improve symptoms. The therapy utilizes an intrathecally delivered antisense oligonucleotide designed to upregulate SYNGAP1 gene expression, potentially increasing SYNGAP protein levels in amounts sufficient to yield therapeutic benefit.
"CMP-SYNGAP-01 (搜索) has demonstrated robust preclinical activity, both restoring SYNGAP1 protein levels to improve phenotypes in a mouse model and increasing SYNGAP1 protein in brain regions of non-human primates that are affected in human disease," said Daniel Tardiff, Ph.D., Chief Scientific Officer of CAMP4. "Our preclinical data gives us confidence in the potential of CMP-SYNGAP-01 to translate into meaningful clinical benefit for patients living with SYNGAP1-related disorders (搜索), and advancing our candidate through GLP toxicology studies marks a critical step towards the clinic."
Preclinical Evidence and Mechanism
Preclinical studies have demonstrated a dose-dependent increase in SYNGAP (搜索) mRNA levels accompanied by an increase in SYNGAP protein expression. The therapy works by targeting regulatory RNAs (regRNAs) that act locally on transcription factors and serve as master regulators of gene expression, utilizing CAMP4's proprietary RAP Platform® technology.
Broader Platform Potential
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. The company's approach amplifies mRNA by harnessing fundamental mechanisms of gene control, with therapeutic antisense oligonucleotide drug candidates designed to target regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders. According to the company, there are more than 1,200 such disorders where a modest increase in protein expression may have the potential to be clinically meaningful.
The initiation of GLP toxicology studies represents a significant step forward for CAMP4's lead program and could potentially establish a new therapeutic paradigm for treating genetic disorders characterized by protein haploinsufficiency. The patient population for SYNGAP1-related disorders (搜索) may be significantly larger than current incidence estimates suggest, indicating substantial commercial potential for a successful therapy.